Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals CRISPR Collaboration by Quarter
CRISPR Collaboration — Cost of sales / collaboration profit-sharing ($M) ($M)
Vertex Pharmaceuticals CRISPR Collaboration: $21.8M in Q2 2026, down 27.6% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR Therapeutics).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CRISPR Collaboration — Cost of sales / collaboration profit-sharing ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 21.8 | -27.6% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 23.1 | -36.2% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 37.2 | +43.1% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 43.3 | +174.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 30.1 | +89.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 36.2 | +129.1% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 26 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 15.8 | – | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 15.9 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 15.8 | – | Form 10-Q (filed 2025-05-06) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals CRISPR Collaboration ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crispr-cogs
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.